Prostaglandin (PG) E 2 is a potent inducer of cortical and trabecular bone formation in humans and animals. Although the bone anabolic action of PGE 2 is well documented, the cellular and molecular mechanisms that mediate this effect remain unclear. This study was undertaken to examine the effect of pharmacological inactivation of the prostanoid receptor EP 4 , one of the PGE 2 receptors, on PGE 2 -induced bone formation in vivo. We first determined the ability of EP 4 A, an EP 4 -selective ligand, to act as an antagonist. PGE 2 increases intracellular cAMP and suppresses apoptosis in the RP-1 periosteal cell line. Both effects were reversed by EP 4 A, suggesting that EP 4 A acts as an EP 4 antagonist in the cells at concentrations consistent with its in vitro binding to EP 4 . We then examined the effect of EP 4 on bone formation induced by PGE 2 in young rats. Five-to 6-week-old rats were treated with PGE 2 (6 mg/kg/day) in the presence or absence of EP 4 A (10 mg/kg/day) for 12 days. We found that treatment with EP 4 A suppresses the increase in trabecular bone volume induced by PGE 2 . This effect is accompanied by a suppression of bone formation indices: serum osteocalcin, extent of labeled surface, and extent of trabecular number, suggesting that the reduction in bone volume is due most likely to decreased bone formation. The pharmacological evidence presented here provides strong support for the hypothesis that the bone anabolic effect of PGE 2 in rats is mediated by the EP 4 receptor.
Prostaglandins, especially PGE 2 , have multiple effects on bone, including stimulation of both resorption and formation (Raisz at al., 1993; reviewed in Bergmann and Schoutens, 1995) . PGE 2 administered to rats in vivo increases cortical as well as trabecular bone mass (Jee et al., 1985 (Jee et al., , 1987 Mori et al., 1990; Suponitzky and Weinreb, 1998) . PGE 1 , an alternate agonist with the same activity spectrum as PGE 2 , was shown to stimulate bone formation and cause hyperostosis in infants (Ueda et al., 1980; Ringel et al., 1982) .
Despite extensive documentation of in vivo bone anabolic effects, the cellular and molecular mechanisms that mediate PGE 2 action remain unclear. In organ culture of fetal rat calvaria, PGE 2 stimulates DNA synthesis in the periosteum, but suppresses collagen production (Raisz and KoolmansBeynen, 1974) . In the mouse MC3T3-E1 osteoblastic cell line, low concentrations of PGE 2 increase cell proliferation, and high concentrations stimulate differentiation (Hakeda et al., 1986) . These effects correlate with an increase in intracellular calcium and cAMP, respectively. In cultures of adult rat calvaria cells, PGE 2 stimulates nodule formation, via a Ca 2ϩ dependent pathway (Kaneki et al., 1999) . In rat RP-11 periosteal cells (Machwate et al., 1998) , PGE 2 increases cell number in vitro by suppressing apoptosis, without affecting proliferation. Similar effects were obtained using PGE 1 and forskolin, suggesting mediation via increased cAMP. It is thus unclear which of these biological responses and intracellular signaling pathways are more relevant to the bone anabolic effects of PGE 2 in vivo. Local administration of PGE 2 or E 1 into long bones in rats stimulates new bone formation (Jee et al., 1985) , suggesting that PGE 2 acts directly on bone tissue to induce osteogenesis. PGEs bind to four subtypes of cell-surface receptors, EP 1-4 (reviewed in Narumiya et al., 1999; Sugimoto et al., 2000) . These receptors belong to the G protein-coupled seven transmembrane domain family of receptors and activate either adenylate cyclase or phospholipase C (PLC). EP 4 and EP 2 activate adenylate cyclase, EP 1 activates PLC, and EP 3 inhibits adenylate cyclase, although EP 3 C-terminal splice variants can activate adenylate cyclase or PLC when expressed in recombinant systems. Prostaglandin receptors are expressed in a wide variety of cells and tissues (reviewed in Narumiya et al., 1999; Sugimoto et al., 2000) . In MC3T3-E1 osteoblastic cells, PGE 2 stimulates both cAMP and phosphatidylinositol signal transduction pathways (Hakeda et al., 1986) . Accordingly, both EP 1 and EP 4 were found to be expressed in these cells (Suda et al., 1996) . In addition, EP 1 , EP 2 , and EP 4 were found to be expressed in preosteoblasts and osteoblasts in fetal bone tissues by in situ hybridization (Kasugai et al., 1995) . EP 3 was found to be expressed in perichondrial cells. Analysis of the role of the individual EP subtypes in PGE 2 action on bone has been relatively limited because of the lack of specificity and limited efficacy of available agonists and antagonists for these receptors (Ono et al., 1998; Kozawa et al., 1998) . However recent findings (Pan et al., 1998) , using mice deficient in EP receptors, showed that those lacking EP 2 or EP 4 have defects in bone metabolism. Interestingly, the EP 4 deficient mice showed a marked decrease in histomorphometric parameters of bone formation as compared with the EP 2 deficient mice. In addition, we found, by Northern blot analysis, that only EP 4 , but not EP 2 , was detected in adult bone tissue. Together these data suggest that among the EP receptors, EP 4 may play a more predominant role in bone anabolic action of PGE 2 .
In this study, we examined the effect of an EP 4 specific antagonist, EP 4 A, on bone formation induced by PGE 2 in young rats. We found that EP 4 A suppresses the increase in bone mass induced by PGE 2 . This effect is accompanied by a reduction in the extent of calcein-labeled surface and trabecular number. Our data suggest that EP 4 is the main receptor through which PGE 2 induces bone formation in rats. Prostanoid receptor radioligand binding assays were conducted as described previously for the human (Abramowitz et al., 2000) and rat receptors (Boie et al., 1997) .
Materials and Methods

Prostanoid
cAMP Measurements. RP-1 periosteal cells, like the RP-11 cells (Machwate et al., 1998) , are spontaneously immortalized from primary cultures of periosteal cells from 4-week old Sprague-Dawley rat tibia and are cultured in DMEM (Life Technologies, Gaithersburg, MD) with 10% fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS). These cells do not express osteoblast phenotypic markers in early culture, but upon confluence, they express several osteoblast markers: type I collagen, alkaline phosphatase, and osteocalcin.
RP-1 cells were plated at 50,000 cells/cm 2 in 96-well plates (Costar, Cambridge, MA) and were cultured for 2 days in DMEM supplemented with 10% FBS. Cells were pretreated with 3-isobutyl-1-methylxanthine (1 M) in DMEM for 10 min. Cells were treated for 10 min with PGE 2 (0.1 M) (Biomol, Plymouth Meeting, PA) in the presence or absence of increasing concentrations of EP 4 A (0-10 M). Cells were lysed and processed for cAMP measurement by radioimmunoassay according to the manufacturer's recommendations (Amersham Pharmacia Biotech, Piscataway, NJ).
Apoptosis. RP-1 cells were plated at 50,000 cells/cm 2 in 24-well plates (Costar, Cambridge, MA) and were cultured for 2 days in DMEM supplemented with 10% FBS. Cells were cultured for 24 h in DMEM supplemented with 2% FBS in the presence or absence of PGE 2 (0.1 M), or in the presence of a combination of PGE 2 (0.1 M) and EP 4 A (10 M). For analysis of apoptosis, the cells were trypsinized (0.25% trypsin, 1 mM EDTA) and single cell suspensions (1-2 million cells/well) were prepared. The cells were washed twice in Ca 2ϩ /Mg 2ϩ -free phosphate-buffered saline (PBS) and fixed in ethanol/PBS (3: 1 v/v) for 30 min. After centrifugation, cells were washed in PBS and processed for terminal deoxynucleotidyl transferase dUTP nick-end labeling staining according to the manufacturer's recommendations (Oncor, Gaithersburg, MD). Briefly, cells were incubated with nucleotide terminal transferase in the presence of dioxygenin-11-dUTP. Labeled cells were identified using an antidigoxigenin, phycoerythrin-conjugated antibody. As control, the samples were exposed to the same mixture excluding the terminal transferase. Staining for annexin-V was analyzed with a FACScan flow cytometer (Becton Dickinson, San Francisco, CA). The red fluorescence was excited at 488 nm by the Argon laser beam. The data acquisition and analysis were performed using cellQuest software (Becton Dickinson, San Francisco, CA).
In Vivo Studies. A total of 40 male Sprague-Dawley rats (Taconic, Germantown, NY), 5-6 weeks old, weighing an average of 135 g at the start of the experiment, were randomly assigned to four groups (n ϭ 10). One group was vehicle-treated (10% ethanol in sterile water), one group was treated with PGE 2 (6 mg/kg/day), one group with the EP 4 antagonist (EP 4 A, 10 mg/kg/day), and the last group was treated with PGE 2 in combination with the EP 4 antagonist (EP 4 A was given 45 min before PGE 2 ). All animals were treated for 12 days by daily intraperitoneal (i.p.) injection. Two days before sacrifice, all animals were given calcein (i.p., 10 mg/kg BW) to label the sites of active mineralization. At sacrifice, the animals were weighed then euthanized by CO 2 inhalation. Blood was collected by cardiac puncture, and tibiae were dissected and processed for histomorphometric analysis. The internal animal experimentation committee approved all protocols.
Plasma Biochemistry. Blood samples were obtained by cardiac puncture and plasma was immediately frozen. The plasma content of osteocalcin was determined by radioimmunoassay using a commercially available kit, according to the manufacturer's recommendations (Immunotopics International, San Clemente, CA).
Histomorphometric Analysis. Tibiae were dissected free from soft tissue, fixed in 10% phosphate-buffered formaldehyde, dehydrated in ethanol, and embedded undecalcified in methylmethacrylate (Baron et al., 1983) . Longitudinal sections (5 m) were cut with a Polycut S microtome (Reichert Jung, Heidelberg, Germany) and examined without further staining for dynamic histomorphometry, or stained with Masson's trichrome for static histological measurements. All histomorphometric measurements were carried out in cancellous bone with a semiautomatic image analysis system (System IV; Bioquant, Nashville, TN). Histomorphometric indices were measured in the proximal metaphyseal area (4 mm 2 ) at a distance of 500 m from the growth plate as described previously (Parfitt et al., 1983) . Trabecular bone volume is expressed as the amount of bone within the spongy space. The mineralizing surface (MS/BS) is calculated as the sum of length of calcein labels and expressed in percent of the bone surface. Trabecular number is the number of bone trabeculae present in the proximal metaphysis within the area of measurement.
Statistical Analysis. Statistical analyses of the data were performed using the statistical package Statview (Abacus Concepts Inc., Berkeley, CA). Differences between treatment groups were tested by one-way ANOVA and unpaired two-tailed Student's t test. P values less than 0.05 at 95% confidence level were considered significant. (Weinreb et al., 2001 ) and in which PGE 2 increases cAMP intracellular levels. RP-1 periosteal cells were treated for 10 min with PGE 2 alone or in combination with increasing concentrations of EP 4 A, then lysed and intracellular cAMP was measured by radioimmunoassay. As shown in Fig. 2A , PGE 2 (0.1 M) increases intracellular cAMP more than 6-fold in this cell line. Treatment with EP 4 A inhibits PGE 2 -induced cAMP increases with an IC 50 value of 0.1 M. To determine whether EP 4 A interferes with PGE 2 -independent accumulation of cAMP, we tested the effect of EP 4 A on intracellular cAMP increased by forskolin. Figure 2B shows that EP 4 A has no effect on intracellular cAMP induced by forskolin, suggesting that the antagonistic effect of EP 4 A on PGE 2 -mediated increase of intracellular cAMP is EP 4 mediated. These data are in agreement with previous results from Schild analysis demonstrating that EP 4 A is a high-affinity competitive antagonist (K B of 3-4 nM) opposing EP 4 -induced increases in cAMP in HEK 293 cells expressing recombinant human EP 4 . EP 4 A did not antagonize cAMP increases induced by forskolin in EP 4 -expressing or EP 4 -deficient HEK 293 cells (data not shown). To further document the efficacy of EP 4 A in antagonizing the PGE 2 effect, we tested the effect of EP 4 A on apoptosis in these cells. Figure 2C shows that, as previously reported for the related RP-11 cells (Machwate et al., 1998) , PGE 2 (0.1 M) suppresses apoptosis measured by annexin-V binding. Cotreatment with EP 4 A (10 M) completely reverses the antiapoptotic effect of PGE 2 . Together with the receptor binding data, these functional data suggest that EP 4 A acts as a specific antagonist for prostanoid receptor EP 4 .
Results
EP
EP 4 A Reverses PGE 2 -Inceased Bone Formation in Rats. PGE 2 was administered at 6 mg/kg/day as described under Materials and Methods. PGE 2 has been known to induce diarrhea and decrease body weight. We therefore monitored the animals and evaluated if EP 4 A interfered with this effect. We observed that diarrhea occurred in the groups treated with PGE 2 regardless of the presence of EP 4 A. Furthermore, we found that treatment with EP 4 A does not effect body weight loss induced by PGE 2 , probably because of the diarrhea induced by PGE 2 acting on the intestine (Fig. 3) . These data suggest that prostaglandin receptor EP 4 may not play a major role in this effect.
As expected, all the bone formation parameters were increased by treatment with PGE 2 . Serum osteocalcin, which is a systemic marker for bone formation activity, increased by about 17% (Fig. 4) . Treatment with EP 4 A completely suppresses the increase in serum osteocalcin (Fig. 4) . Trabecular bone volume in the tibial metaphysis increased by 66% (Fig.  5, A & C) . These effects were associated with increases in structural and dynamic histomorphometric indices of bone formation. Indeed, both the trabecular number (Fig. 5D ) and the extent of calcein-labeled surface (Fig. 5B) increased by 28 and 70%, respectively. Treatment with EP 4 A alone has no significant effect on all the above markers. However, when EP 4 A was given in combination with PGE 2, it reversed the increase in bone formation markers induced by PGE 2 and maintained them at control levels. Relative to PGE 2 treated animals, EP 4 A decreased trabecular bone volume by 81% (Fig. 5C) , trabecular number by 93% (Fig. 5D) , and the calcein-labeled surface by 54% (Fig. 5B ). These data show that an EP4 antagonist suppresses the bone anabolic effect of PGE2 and suggest that the EP 4 receptor mediates PGE 2 effects on bone formation. 
Discussion
The present study demonstrates that pharmacological inactivation of prostanoid receptor EP 4 with EP 4 A suppresses PGE 2 -induced bone formation in vivo. PGE 2 and its analog PGE 1 are potent inducers of osteogenesis in humans (Ueda et al., 1980; Ringel et al., 1982) and animals (Jee et al., 1985 (Jee et al., , 1987 Mori et al., 1990; Suponitzky and Weinreb, 1998) ; however, the EP receptor that mediates osteogenic effects of PGE 2 has not been identified previously. In vitro studies did not provide conclusive evidence as to which EP subtype (EP 1 , EP 2 , EP 3 , or EP 4 ) mediates the anabolic effects of PGE 2 . This is mainly because PGE 2 has variable in vitro effects, depending on the osteoblastic cell type used (Raisz and KoolmansBeynen, 1974; Hakeda et al., 1986; Kaneki et al., 1999) , as stated in the introduction. In addition, the agonists and/or antagonists used so far to study PGE effects on bone were not sufficiently selective for the individual EP subtypes (Kozawa et al., 1998; Ono et al., 1998) .
The genetic inactivation of EP subtypes in mice has provided evidence that prostanoid receptor EP 4 mediates PGE 2 -induced bone resorption in mice (Ono et al., 1998; Suzawa et al., 2000) . Indeed, studies of osteoclast formation in vitro showed that induction of this process depends on the presence of EP 4 in osteoblastic cells. These data are supported by recent in vivo findings showing that PGE 2 -increased bone resorption is abrogated in these EP 4 deficient (Perry et al., 2000) . On the other hand, another study, using EP 2 deficient mice, showed that EP 2 mediates, at least partially, the induction of bone resorption induced by thyroparathyroidectomy (Tomita et al., 1999) . As mentioned above, PGE 2 can stimulate both bone resorption and formation in vivo. These effects are species specific, which should be considered when interpreting the data from gene deletion studies in mice. In mice, PGE 2 is a strong stimulator of bone resorption compared with rats and humans, in which PGE 2 predominantly increases bone formation. A pharmacological approach aimed at specifically targeting EP subtypes, therefore, is better suited for identifying which receptors mediate PGE 2 effects on bone in rats.
EP 4 A, the EP 4 antagonist used in this study, is highly selective for EP 4 . This compound displays a K i value for binding to rat EP 4 that is at least 225-fold lower than the K i values determined at rat EP 1 , EP 2 , and EP 3 . We also showed pharmacologically that EP 4 A acts as a PGE 2 antagonist, in that it dose-dependently inhibited PGE 2 -induction of intracellular cAMP formation in a responsive cell line, RP-1. In addition, EP 4 A reverses a cAMP-mediated biological effect of PGE 2 in these cells, the suppression of apoptosis. Pharmacokinetic studies (data not shown) showed that EP 4 A reaches 1 M in the blood 1 h after intraperitoneal injection with an estimated half-life of 3 h. EP 4 A, therefore, is a highly selective antagonist for EP 4 with appropriate pharmacokinetic properties for in vivo studies evaluating pharmacologically the function of EP 4 in PGE 2 action on bone formation. Treatment with EP 4 A suppressed PGE 2 -induced increases in trabecular bone volume, suppressed serum osteocalcin and reduced the extent of calcein-labeled bone surface and trabecular number. These findings indicate that the reduction in bone volume is most likely a result of decreased bone formation.
The cellular mechanisms that mediate the bone anabolic effects of PGE 2 are still unclear and require further study. We have previously shown that PGE 2 increases periosteal cell number in vitro by suppressing apoptosis, without affecting proliferation. Similar effects were obtained using PGE 1 and forskolin, indicating cAMP mediation (Machwate et al., 1998) . Interestingly, parathyroid hormone, which also stimulates bone formation and intracellular cAMP accumulation, was found to increase osteoblast number in vivo without increasing proliferation (Dobnig and Turner, 1995; Jilka et al., 1999) . PGE 2 , which may act via a mechanism similar to that of parathyroid hormone, may prolong the life span of bone forming cells and thereby increase their number. The role of apoptosis and cellular life span in the anabolic effect of PGE 2 in vivo remains to be documented. Future in vivo studies, potentially using EP 4 A, will be necessary to determine the extent to which regulation of osteoblast apoptosis plays a role in PGE 2 bone anabolic effects.
was embedded undecalcified. Frontal sections (5 m) were stained with Masson's trichrome and subjected to quantitative histologic analysis. A, photomicrographs representative of the area of secondary spongiosa from which data were collected. The bone is stained blue, and the marrow stroma stained red. Scale bar, 0.1 mm. B, calcein-labeled surface, MS/BS (calcein labeled surface as a percentage of total bone surface). C, trabecular or cancellous bone volume, BV/TV (cancellous bone volume as a percentage of total bone volume). D, trabecular number, Tb. N, trabecular number per square millimeter of total tissue volume). Data are reported as mean Ϯ S.E.M. *p Ͻ 0.01 versus vehicle-treated group; **p Ͻ 0.05 versus PGE 2 -treated group 
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This is the first study demonstrating the use of a selective PGE 2 receptor antagonist, targeting EP 4 , to elucidate the role of EP 4 in in vivo effects of PGE 2 on bone. Further studies using a similar approach with an EP 4 agonist and ligands that target the other EP receptors are necessary to evaluate whether EP 4 is the only or major prostanoid receptor that mediates the bone anabolic effects of PGE 2 in rats.
